TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06191965
Drug: MitoQ
Normalized name: Mitoquinone
DrugBank: Mitoquinone (DB05063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ.
Study: NCT06003231
Drug: disitamab vedotin
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given into the vein (IV, intravenous) every 2 weeks
Study: NCT05109364
Drug: Terazosin therapy
DrugBank: Terazosin (DB01162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
Study: NCT06009107
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously.
Study: NCT06260722
Drug: Retatrutide
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06260722
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC.
Study: NCT04821622
Drug: talazoparib plus enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: experimental arm
Study: NCT04821622
Drug: Placebo plus enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active comparator arm
Study: NCT05423106
Drug: JNJ-64457744
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64457744 will be administered as oral solution.
Study: NCT05423106
Drug: Tenofovir Disoproxil Fumarate (TDF)
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDF tablet will be administered orally
Study: NCT05423106
Drug: Tenofovir Alafenamide (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAF tablet will be administered orally.
Study: NCT05423106
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETV tablet will be administered orally.
Study: NCT05423106
Drug: JNJ-64457744
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64457744 will be administered as oral tablet.
Study: NCT04305158
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient receiving nitrous oxide are evaluated for success of the procedure
Study: NCT04963738
Drug: JNJ-73763989
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-73763989 will be administered as a single SC injection.
Study: NCT05379803
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: furmonertinib 160 mg orally QD
Study: NCT05076981
Drug: human chorionic gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
Study: NCT04659044
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05172258
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04732117
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.
Study: NCT04659044
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06297083
Drug: Peanut Oral Powder [PEANUT POWDER]
Normalized name: Peanut Oral Powder [PEANUT POWDER]
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months
Study: NCT05518812
Drug: Carboprost Tromethamine
Normalized name: Carboprost Tromethamine
DrugBank: Carboprost tromethamine (DB00429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
Study: NCT06191458
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine 0.5 mg/kg (Government Pharmaceutical Organization, Thailand) will be given once daily with food for 14 days. This is the dose recommended by the World Health Organization for radical cure of P. vivax in tropical regions. Doses will be directly supervised (DOT).
Study: NCT05158244
Drug: PF-07081532
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug, once daily for 42 days
Study: NCT02307812
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously (IV)
Study: NCT02307812
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT04825574
Drug: Avapritinib
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: avapritinib tablet
Study: NCT06595979
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.
Study: NCT06598735
Drug: HRS-4508
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-4508
Study: NCT06651749
Drug: Propofol injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.
Study: NCT06588335
Drug: BTLA inhibitor (JS004)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;
Study: NCT06588335
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab:240mg,intravenous infusion, d1, Q3W;
Study: NCT06588335
Drug: Paclitaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;
Study: NCT06070766
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The use of ketamine in chronic conditions.
Study: NCT06585995
Drug: vitamin D (cholecalciferol) supplementation
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This pilot clinical study administered and compared daily and bolus vitamin D dosing regimens to achieve and maintain optimal serum 25(OH)D levels in patients with COVID-19. The daily dose group received constant cholecalciferol supplementation (vitamin D supplementation), aimed at achieving more stable and non-peak 25(OH)D levels. In contrast, the bolus group received a one-month cumulative monthly dose, divided into 4 doses, administered on 4 consecutive days, which could result in rapid increases followed by gradual decreases in 25(OH)D levels. The daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .~Bolus dose = (daily dose)(30 days)/4 doses
Study: NCT06601530
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
Study: NCT05364944
Drug: Debio 4126
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injection
Study: NCT05364944
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
Study: NCT05364944
Drug: Somatuline ATG
Normalized name: Somatuline
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
Study: NCT05734196
Drug: INZ-701
Normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Study: NCT02944955
Drug: BLEX 404 Oral Liquid
Normalized name: Bleximenib
DrugBank: Bleximenib (DB19328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks.
Study: NCT06131840
Drug: PF-08046050
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given into the vein (IV; intravenous)
Study: NCT06530641
Drug: Buckberg Cardi-Braun
Normalized name: pork brain preparation
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Buckberg blood cardioplegia.
Study: NCT05097287
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: solution for injection subcutaneous
Study: NCT04709601
Drug: Hiprex
Normalized name: Hiprex
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
Study: NCT05192889
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given oral (PO).
Study: NCT05192889
Drug: Navitoclax
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given oral (PO).
Study: NCT05192889
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally (PO) or intravenously (IV).
Study: NCT05192889
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV).
Study: NCT05192889
Drug: Calaspargase Pegol
Normalized name: Calaspargase pegol
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV).
Study: NCT05192889
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given oral (PO).
Study: NCT05192889
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV) or Intrathecal (IT).
Study: NCT05192889
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV).
Study: NCT05192889
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
Study: NCT05192889
Drug: Erwinia asparaginase
Normalized name: Erwinia asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
Study: NCT04721223
Drug: JAB-3068
Normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAB-3068 administrated orally as a tablet.
Study: NCT04721223
Drug: PD1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JS001 administrated as an intravenous(IV) infusion.
Study: NCT00270010
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05183178
Drug: Prasugrel 10 mg p.o
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel 10 mg once daily p.o. Patient \>75 years of age or \<60 kg will receive 5 mg prasugrel OD.
Study: NCT05183178
Drug: Ticagrelor 90 mg
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily p.o.
Study: NCT05177510
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progestin Antagonist
Study: NCT06018766
Drug: LAM-001
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM-001 administered via dry powder inhaler
Study: NCT00001116
Drug: Tumor Necrosis Factor soluble receptor-immunoadhesin complex
Normalized name: Tumor necrosis factor, soluble form, nonglycosylated
DrugBank: Tasonermin (DB11626)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04473989
Drug: recombinant teriparatide for injection
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: weekly subcutaneous administration of 40 ug
Study: NCT06588660
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT04621981
Drug: Sodium Bicarbonate Ringer's Solution
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group was treated with Sodium Bicarbonate Ringer's Solution.
Study: NCT05387980
Drug: CIBINQO
Normalized name: Cibinqo
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
Study: NCT05384249
Drug: Izokibep
Normalized name: Izokibep
DrugBank: Izokibep (DB19081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study: NCT05691010
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
Study: NCT05691010
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
Study: NCT05367440
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive an oral dose of Enzalutamide once daily
Study: NCT05367440
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive an oral dose of Abiraterone Acetate once daily
Study: NCT05367440
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive an oral dose of Darolutamide twice daily
Study: NCT05367440
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive an oral dose of Apalutamide once daily
Study: NCT06077864
Drug: survodutide
Normalized name: Survodutide
DrugBank: Survodutide (DB18989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly subcutaneous injection
Study: NCT05177419
Drug: Lysergic Acid Diethylamide
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms LSD base
Study: NCT05177419
Drug: Lysergic Acid Diethylamide
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of LSD base
Study: NCT06049589
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine rinsing
Study: NCT06681090
Drug: 0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott). The medication was to be used 3 times every day for 4 weeks or until the lesion has healed, whichever occurs first. After applying the gel, the patients were instructed not to consume any fluids or food for at least 1 hour. In addition, a topical antifungal treatment consisting of Miconazole oral gel at a concentration of 2% should be applied once a day for 4 weeks
Study: NCT05464329
Drug: Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided by Genentech.
Study: NCT05464329
Drug: DHAX
Normalized name: Dihydroartemisinin-Piperaquine
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
Study: NCT05464329
Drug: ICE
Normalized name: Ice
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
Study: NCT05844592
Drug: INV-101
Normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subjects will be randomized 3:1 ratio
Study: NCT05021328
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240mg, ivgtt, d1, q3w.
Study: NCT05021328
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12 mg/d, d1-14, q3w.
Study: NCT06502145
Drug: Azacitidine Level -1
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
Study: NCT06502145
Drug: Azacitidine Level 0
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
Study: NCT06502145
Drug: Azacitidine Level 1
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
Study: NCT06502145
Drug: Iadademstat Level -1
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.
Study: NCT06502145
Drug: Iadademstat Level 0
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
Study: NCT06502145
Drug: Iadademstat Level 1
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
Study: NCT04908579
Drug: bupivacaine(intraperitoneally) and ketamine (intraperitoneally)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous.
Study: NCT04908579
Drug: bupivacaine(intraperitoneally) and ketamine (intravenously)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites.
Study: NCT04908579
Drug: bupivacaine(intraperitoneally)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous.
Study: NCT05666518
Drug: Vericiguat (Verquvo, BAY1021189)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage at the discretion of the treating physician, based on the recommendations written in the product information.